Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | Chief Legal & Admin Officer | March 15, 2026 | March 17, 2026 |
| EXELIXIS, INC.EXEL · Entity 3386 | EVP & General Counsel | May 15, 2025 | May 17, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date March 15, 2026 · Filed March 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 107,943 |
Reported balance
After 2026-03-15 transaction · row 1
1 source rowRow 1 · 2026-03-15 · Grant · Acquired 20,646 · Balance 107,943 F1: Annual equity award comprised of restricted stock units ("RSUs") that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 40% of the RSUs on the 1-year anniversary of the grant date, an additional 40% of the RSUs on the 2-year anniversary of the grant date, and the final 20% of the RSUs on the 3-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan. |
| Incentive Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.06 · Expires 2036-03-14 | Direct | 8,325 |
Reported balance
After 2026-03-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-15 · Grant · Acquired 8,325 · Balance 8,325 F2: Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.06 · Expires 2036-03-14 | Direct | 22,820 |
Reported balance
After 2026-03-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-15 · Grant · Acquired 22,820 · Balance 22,820 F3: Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual equity award comprised of restricted stock units ("RSUs") that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 40% of the RSUs on the 1-year anniversary of the grant date, an additional 40% of the RSUs on the 2-year anniversary of the grant date, and the final 20% of the RSUs on the 3-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
F2: Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
F3: Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
EXELIXIS, INC.
Report date May 15, 2025 · Filed May 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 693,396 |
Last balance in matching sequence
After 2025-05-15 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2025-05-15 · Tax withholding · Disposed 34,035 · Balance 718,396 F1: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded on March 4, 2021, March 4, 2022, April 3, 2023, and February 23, 2024. F2: Includes 369,995 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs") and 753 shares of Common Stock acquired on April 30, 2025, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock. Row 2 · 2025-05-15 · Sale · Disposed 25,000 · Balance 693,396 F3: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $46.04 to $46.48. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. F2: Includes 369,995 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs") and 753 shares of Common Stock acquired on April 30, 2025, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) | 999 |
Reported balance
Holding disclosure · report date 2025-05-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 999 F4: Represents shares of Common Stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 14, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded on March 4, 2021, March 4, 2022, April 3, 2023, and February 23, 2024.
F2: Includes 369,995 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs") and 753 shares of Common Stock acquired on April 30, 2025, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock.
F3: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $46.04 to $46.48. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
F4: Represents shares of Common Stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 14, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2026 Filed Mar 17, 2026 20:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 22,820 | $0.00 Strike: $60.06 | $0.00 |
DisclosureSEC source: 0001061983-26-000022 · form4.xml · derivative · entry 3 Hessekiel Jeffrey · CIK 0001599803 · Chief Legal & Admin Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,820 Underlying: Common Stock · 22,820 shares Expires 2036-03-14 F3 · kind: Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (Right to Buy) · Derivative | 8,325 | $0.00 Strike: $60.06 | $0.00 |
DisclosureSEC source: 0001061983-26-000022 · form4.xml · derivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · Chief Legal & Admin Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,325 Underlying: Common Stock · 8,325 shares Expires 2036-03-14 F2 · kind: Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 20,646 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-26-000022 · form4.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · Chief Legal & Admin Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,943 F1 · kind: Annual equity award comprised of restricted stock units ("RSUs") that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 40% of the RSUs on the 1-year anniversary of the grant date, an additional 40% of the RSUs on the 2-year anniversary of the grant date, and the final 20% of the RSUs on the 3-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan. Read SEC document |
| November 14, 2025 Filed Nov 17, 2025 21:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 87,297 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-25-000036 · form4.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · Chief Legal & Admin Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,297 F1 · kind: Initial new hire grant comprised of restricted stock units ("RSUs") that are convertible to shares of common stock on a 1:1 basis upon vesting. RSUs will vest as follows: 40% of the aggregate RSUs on the date falling 1-year from the date of grant, an additional 40% of the aggregate RSUs on the date falling 2-years from the date of grant, and the remaining 20% of the aggregate RSUs on the date falling 3-years from the date of grant, in each case subject to Mr. Hessekiel's continued employment with Cytokinetics. Read SEC document |
| May 15, 2025 Filed May 17, 2025 00:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 25,000 | $46.18 | $1,154,500.00 |
DisclosureSEC source: 0000939767-25-000078 · wk-form4_1747443441.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 693,396 F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $46.04 to $46.48. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. F2 · balance_after: Includes 369,995 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs") and 753 shares of Common Stock acquired on April 30, 2025, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| May 15, 2025 Filed May 17, 2025 00:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 34,035 | $44.65 | $1,519,662.75 |
DisclosureSEC source: 0000939767-25-000078 · wk-form4_1747443441.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 718,396 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded on March 4, 2021, March 4, 2022, April 3, 2023, and February 23, 2024. F2 · balance_after: Includes 369,995 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs") and 753 shares of Common Stock acquired on April 30, 2025, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| March 31, 2025 Filed Mar 31, 2025 23:43 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 154,070 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-25-000052 · wk-form4_1743464586.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 751,678 F1 · shares: Represents an award of performance-based restricted stock units (each, a "PSU") that was granted to the Reporting Person on the Transaction Date pursuant to the 2017 Equity Incentive Plan. Each PSU represents a contingent right to receive one share of Exelixis, Inc. common stock ("Common Stock"). The PSUs vest upon satisfaction of both (i) a performance-based condition requiring the volume-weighted average closing price of the Common Stock to equal or exceed $60 per share for any consecutive 90-calendar-day period during a five-year performance period, and (ii) a service-based condition requiring employment through the fifth anniversary of the grant date (except in the event of certain qualifying terminations of employment). F2 · balance_after: Includes 437,015 shares of Common Stock that will be issued to the Reporting Person upon the vesting of restricted stock units (each, an "RSU") and the PSUs. Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| February 26, 2025 Filed Mar 1, 2025 01:35 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 52,192 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-25-000041 · wk-form4_1740792901.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 597,608 F1 · security: Represents shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. F2 · date: The RSUs were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The RSUs will vest as to 1/4th of the original number of shares subject to the RSU award on May 15, 2026 and thereafter as to 1/4th of the original number of shares subject to the RSU award on each May 15th until fully vested. F3 · balance_after: Includes 282,945 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs. Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 01:31 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 18,134 | $35.00 | $634,690.00 |
DisclosureSEC source: 0000939767-25-000025 · wk-form4_1740015111.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 545,416 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on March 4, 2021, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on January 11, 2024. F2 · balance_after: Includes 230,753 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| January 16, 2025 Filed Jan 18, 2025 02:45 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 26,289 | $37.27 | $979,791.03 |
DisclosureSEC source: 0000939767-25-000007 · wk-form4_1737168313.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 563,550 F4 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of PSU awarded on March 4, 2022, for which the Committee certified that Exelixis, Inc. had achieved certain performance criteria on January 16, 2025. Read SEC document |
| January 16, 2025 Filed Jan 18, 2025 02:45 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 118,780 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-25-000007 · wk-form4_1737168313.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 589,839 F1 · date: On March 4, 2022, the Reporting Person was granted a performance-based restricted stock unit award ("PSU") under the Exelixis, Inc. 2017 Equity Incentive Plan covering 67,875 shares of common stock (such shares, the "Target Shares"). The PSU generally vests as follows: (i) 50% of the eligible Target Shares vest upon the Compensation Committee's (the "Committee") certification of achievement of certain performance criteria; and (ii) 50% of the eligible Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the PSU provides for vesting of up to a maximum of 175% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the PSU. F2 · shares: On January 16, 2025, the Committee determined that certain performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 175% of the Target Shares subject to the PSU (such shares, the "Achieved Shares"). Accordingly, the Committee's certification on January 16, 2025 resulted in the immediate vesting of 50% of the Achieved Shares, and 50% of the Achieved Shares will vest on February 15, 2026, subject to the Reporting Person's continuous service through that date. F3 · balance_after: Includes 266,463 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 01:29 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GiftCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-24-000165 · wk-form4_1733189339.xml · nonDerivative · entry 4 Hessekiel Jeffrey · CIK 0001599803 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 471,059 F4 · kind: On November 29, 2024, the Reporting Person gifted 15,000 shares of Common Stock. F1 · balance_after: Includes 207,072 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 01:29 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 60,000 | $36.67 | $2,200,200.00 |
DisclosureSEC source: 0000939767-24-000165 · wk-form4_1733189339.xml · nonDerivative · entry 3 Hessekiel Jeffrey · CIK 0001599803 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 486,059 F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $36.36 to $36.93. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. F1 · balance_after: Includes 207,072 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| November 27, 2024 Filed Dec 3, 2024 01:29 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 129,314 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0000939767-24-000165 · wk-form4_1733189339.xml · derivative · entry 6 Hessekiel Jeffrey · CIK 0001599803 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 129,314 shares Expires 2025-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 129,314 shares of Common Stock, became fully exercisable on September 10, 2022. Read SEC document |
| November 27, 2024 Filed Dec 3, 2024 01:29 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 98,908 | $35.93 | $3,553,764.44 |
DisclosureSEC source: 0000939767-24-000165 · wk-form4_1733189339.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 546,059 F2 · shares: Represents a "net exercise" of an outstanding stock option to purchase 129,314 shares, and pursuant to which the Reporting Person received 30,406 shares, of Common Stock. The Issuer withheld 98,908 shares of Common Stock underlying the stock option for payment of the exercise price and tax withholding using the closing stock price on November 27, 2024 of $35.93. F1 · balance_after: Includes 207,072 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| November 27, 2024 Filed Dec 3, 2024 01:29 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 129,314 | $18.80 | $2,431,103.20 |
DisclosureSEC source: 0000939767-24-000165 · wk-form4_1733189339.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 644,967 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 207,072 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| November 15, 2024 Filed Nov 20, 2024 01:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 14,672 | $35.05 | $514,253.60 |
DisclosureSEC source: 0000939767-24-000160 · wk-form4_1732064574.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 515,653 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 11, 2020, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on September 6, 2023. F2 · balance_after: Includes 207,072 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| November 01, 2024 Filed Nov 6, 2024 00:05 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 50,000 | $34.13 | $1,706,500.00 |
DisclosureSEC source: 0000939767-24-000156 · wk-form4_1730851494.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 530,325 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 29, 2024. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $34.00 to $34.36. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. F3 · balance_after: Includes 236,022 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| October 28, 2024 Filed Oct 30, 2024 22:04 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 25,000 | $28.39 | $709,750.00 |
DisclosureSEC source: 0000939767-24-000152 · wk-form4_1730325874.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 580,325 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 29, 2024. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $28.11 to $28.53. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. F3 · balance_after: Includes 236,022 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| September 23, 2024 Filed Sep 25, 2024 23:32 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 25,000 | $26.38 | $659,500.00 |
DisclosureSEC source: 0000939767-24-000132 · wk-form4_1727307170.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 605,325 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 29, 2024. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.18 to $26.58. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. F3 · balance_after: Includes 236,022 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 23:07 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 20,000 | $0.00 Strike: $24.41 | $0.00 |
DisclosureSEC source: 0000939767-24-000131 · wk-form4_1724886421.xml · derivative · entry 4 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2024-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 100,000 shares of Exelixis, Inc. common stock became fully exercisable on October 3, 2021. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 23:07 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 20,000 | $25.79 | $515,800.00 |
DisclosureSEC source: 0000939767-24-000131 · wk-form4_1724886421.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 630,325 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 29, 2024. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.68 to $25.87. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. F1 · balance_after: Includes 236,022 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 23:07 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 20,000 | $24.41 | $488,200.00 |
DisclosureSEC source: 0000939767-24-000131 · wk-form4_1724886421.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 650,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 236,022 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock. Read SEC document |
| August 07, 2024 Filed Aug 9, 2024 23:32 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 80,000 | $0.00 Strike: $24.41 | $0.00 |
DisclosureSEC source: 0000939767-24-000124 · wk-form4_1723246314.xml · derivative · entry 4 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 80,000 shares Expires 2024-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 100,000 shares of Exelixis, Inc. common stock became fully exercisable on October 3, 2021. Read SEC document |
| August 07, 2024 Filed Aug 9, 2024 23:32 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 80,000 | $25.97 | $2,077,600.00 |
DisclosureSEC source: 0000939767-24-000124 · wk-form4_1723246314.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 630,325 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 29, 2024. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.95 to $26.07. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. F1 · balance_after: Includes 236,022 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 07, 2024 Filed Aug 9, 2024 23:32 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 80,000 | $24.41 | $1,952,800.00 |
DisclosureSEC source: 0000939767-24-000124 · wk-form4_1723246314.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 710,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 236,022 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 15, 2024 Filed May 17, 2024 23:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 10,101 | $20.99 | $212,019.99 |
DisclosureSEC source: 0000939767-24-000068 · wk-form4_1715990263.xml · nonDerivative · entry 3 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 630,325 F4 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded April 3, 2023. F2 · balance_after: Includes 287,204 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 1,214 shares of Exelixis, Inc. common stock acquired on April 30, 2024, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Read SEC document |
| May 15, 2024 Filed May 17, 2024 23:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 8,600 | $20.99 | $180,514.00 |
DisclosureSEC source: 0000939767-24-000068 · wk-form4_1715990263.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 640,426 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded March 4, 2022. F2 · balance_after: Includes 287,204 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 1,214 shares of Exelixis, Inc. common stock acquired on April 30, 2024, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Read SEC document |
| May 15, 2024 Filed May 17, 2024 23:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 7,240 | $20.99 | $151,967.60 |
DisclosureSEC source: 0000939767-24-000068 · wk-form4_1715990263.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 649,026 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded March 4, 2021. F2 · balance_after: Includes 287,204 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 1,214 shares of Exelixis, Inc. common stock acquired on April 30, 2024, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 23:58 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 63,350 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-24-000031 · wk-form4_1709078285.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 655,052 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2025 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested. F3 · balance_after: Includes 287,204 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| January 11, 2024 Filed Jan 17, 2024 01:50 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 13,061 | $22.86 | $298,574.46 |
DisclosureSEC source: 0000939767-24-000018 · wk-form4_1705456220.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 591,702 F4 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on January 11, 2024. F3 · balance_after: Includes 223,854 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| January 11, 2024 Filed Jan 17, 2024 01:50 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 71,418 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-24-000018 · wk-form4_1705456220.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 604,763 F1 · date: On March 4, 2021, the Reporting Person was granted a performance-based restricted stock unit award ("PSU") under the Exelixis, Inc. 2017 Equity Incentive Plan covering 57,135 shares of common stock (such shares, the "Target Shares"). The PSU generally vests as follows: (i) 50% of the eligible Target Shares vest upon the Compensation Committee's (the "Committee") certification of achievement of certain performance criteria; and (ii) 50% of the eligible Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the PSU provides for vesting of up to a maximum of 200% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the PSU. F2 · shares: On January 11, 2024, the Committee determined that certain performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 125% of the Target Shares subject to the PSU (such shares, the "Achieved Shares"). Accordingly, the Committee's certification on January 11, 2024 resulted in the immediate vesting of 50% of the Achieved Shares, and 50% of the Achieved Shares will vest on February 15, 2025, subject to the Reporting Person's continuous service through that date. F3 · balance_after: Includes 223,854 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 00:55 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 25,000 | $23.01 | $575,250.00 |
DisclosureSEC source: 0000939767-23-000123 · wk-form4_1702601738.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 533,345 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 23, 2022. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.00 to $23.06. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. F3 · balance_after: Includes 188,144 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| December 04, 2023 Filed Dec 4, 2023 23:22 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 25,000 | $22.06 | $551,500.00 |
DisclosureSEC source: 0000939767-23-000120 · wk-form4_1701732133.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 558,345 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 23, 2022. F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.00 to $22.16. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. F3 · balance_after: Includes 188,144 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 30, 2023 Filed Dec 4, 2023 23:22 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 25,000 | $22.01 | $550,250.00 |
DisclosureSEC source: 0000939767-23-000120 · wk-form4_1701732133.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 583,345 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 23, 2022. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.00 to $22.07. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. F3 · balance_after: Includes 188,144 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 06, 2023 Filed Sep 9, 2023 01:22 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 14,354 | $22.27 | $319,663.58 |
DisclosureSEC source: 0000939767-23-000103 · wk-form4_1694222563.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 608,345 F4 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on September 6, 2023. F3 · balance_after: Includes 188,144 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 06, 2023 Filed Sep 9, 2023 01:22 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 57,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-23-000103 · wk-form4_1694222563.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 622,699 F1 · date: On September 11, 2020, the Reporting Person was granted a performance-based restricted stock unit award ("PSU") under the Exelixis, Inc. 2017 Equity Incentive Plan covering 57,900 shares of common stock (such shares, the "Target Shares"). The PSU generally vests as follows: (i) 50% of the eligible Target Shares vest upon the Compensation Committee's (the "Committee") certification of achievement of certain performance criteria; and (ii) 50% of the eligible Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the PSU provides for vesting of up to a maximum of 200% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the PSU. F2 · shares: On September 6, 2023, the Committee determined that certain performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 150% of the Target Shares subject to the PSU (such shares, the "Achieved Shares"). The Reporting Person had already vested 1/3 of the Achieved Shares as a result of the Committee's certification that certain performance criteria had been achieved on August 3, 2022 and continuous service through August 15, 2023. Accordingly, the Committee's certification on September 6, 2023 resulted in the immediate vesting of 1/3 of the Achieved Shares, and 1/3 of the Achieved Shares will vest on November 15, 2024, subject to the Reporting Person's continuous service through that date. The Reporting Person remains eligible for additional vesting depending on the level and timing of achievement of the performance criteria through December 31, 2024. F3 · balance_after: Includes 188,144 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 15, 2023 Filed Aug 18, 2023 00:17 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 7,177 | $21.51 | $154,377.27 |
DisclosureSEC source: 0000939767-23-000088 · wk-form4_1692317835.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 564,799 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 11, 2020, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on August 3, 2022. F2 · balance_after: Includes 159,194 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 01, 2023 Filed Aug 4, 2023 00:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 55,710 | $0.00 Strike: $14.74 | $0.00 |
DisclosureSEC source: 0000939767-23-000081 · wk-form4_1691107335.xml · derivative · entry 4 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,710 shares Expires 2023-09-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 97,500 shares of Exelixis, Inc. common stock, became fully exercisable on September 22, 2020. Read SEC document |
| August 01, 2023 Filed Aug 4, 2023 00:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 55,710 | $19.63 | $1,093,587.30 |
DisclosureSEC source: 0000939767-23-000081 · wk-form4_1691107335.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 571,976 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 23, 2022. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.55 to $19.79. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| August 01, 2023 Filed Aug 4, 2023 00:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 55,710 | $14.74 | $821,165.40 |
DisclosureSEC source: 0000939767-23-000081 · wk-form4_1691107335.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 627,686 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 173,669 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 15, 2023 Filed May 18, 2023 00:20 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 7,027 | $19.18 | $134,777.86 |
DisclosureSEC source: 0000939767-23-000053 · wf-form4_168436918098485.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 571,976 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded March 4, 2022. Read SEC document |
| May 15, 2023 Filed May 18, 2023 00:20 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 4,940 | $19.18 | $94,749.20 |
DisclosureSEC source: 0000939767-23-000053 · wf-form4_168436918098485.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 579,003 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded March 4, 2021. F2 · balance_after: Includes 173,669 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 1,508 shares of Exelixis, Inc. common stock acquired on April 28, 2023, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Read SEC document |
| April 05, 2023 Filed Apr 6, 2023 00:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 13,930 | $0.00 Strike: $14.74 | $0.00 |
DisclosureSEC source: 0000939767-23-000041 · wf-form4_168074265582525.xml · derivative · entry 5 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,710 Underlying: Common Stock · 13,930 shares Expires 2023-09-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option, representing the right to purchase a total of 97,500 shares of Exelixis, Inc. common stock, became fully exercisable on September 22, 2020. Read SEC document |
| April 05, 2023 Filed Apr 6, 2023 00:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 38,930 | $20.01 | $778,989.30 |
DisclosureSEC source: 0000939767-23-000041 · wf-form4_168074265582525.xml · nonDerivative · entry 3 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 582,435 F4 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 23, 2022. F5 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.06. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 5 to this Form 4. Read SEC document |
| April 05, 2023 Filed Apr 6, 2023 00:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 13,930 | $14.74 | $205,328.20 |
DisclosureSEC source: 0000939767-23-000041 · wf-form4_168074265582525.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 621,365 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2023 Filed Apr 6, 2023 00:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 79,719 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-23-000041 · wf-form4_168074265582525.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 607,435 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2024 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested. F3 · balance_after: Includes 204,921 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:59 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 27,860 | $0.00 Strike: $14.74 | $0.00 |
DisclosureSEC source: 0000939767-23-000030 · wf-form4_167789158170498.xml · derivative · entry 4 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,640 Underlying: Common Stock · 27,860 shares Expires 2023-09-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 97,500 shares of Exelixis, Inc. common stock, became fully exercisable on September 22, 2020. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:59 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 77,860 | $17.13 | $1,333,741.80 |
DisclosureSEC source: 0000939767-23-000030 · wf-form4_167789158170498.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 527,716 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 23, 2022. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.28. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:59 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 27,860 | $14.74 | $410,656.40 |
DisclosureSEC source: 0000939767-23-000030 · wf-form4_167789158170498.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 605,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 125,202 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.